Moral distress arises not only from organizational constraints on moral action but also from the environmental impacts of health care and climate change.
AMA J Ethics. 2017;19(6):617-628. doi:
10.1001/journalofethics.2017.19.6.mhst1-1706.
Climate is a primary determinant of whether a particular location has the environmental conditions suitable for the transmission of several vector-borne diseases, including dengue fever, St. Louis encephalitis, and West Nile virus.
When the health care industry came under the environmental microscope, the daily work of treating patients was discovered to be highly wasteful of natural and financial resources.
In clinical settings, chaplains are key communicators who help mediate between patients, families, and the medical team. This month on Ethics Talk, we explore how chaplains help patients and families articulate their goals and navigate logistical and emotional challenges that arise in the hospital.
Sabhyta Sabharwal, MPH, Jason W. Mitchell, PhD, MPH, and Victoria Y. Fan, ScD, SM
The World Health Organization and American Academy of Pediatrics recommend disclosing serostatus to sexually active adolescents. What else can be done to improve clinical outcomes and promote public health?
AMA J Ethics. 2018;20(8):E743-749. doi:
10.1001/amajethics.2018.743.
Nicole Martinez-Martin, JD, PhD, Laura B. Dunn, MD, and Laura Weiss Roberts, MD, MA
Calibrating a machine learning model with data from a local setting is key to predicting psychosis outcomes. Clinicians also need to understand an algorithm’s limitations and disclose clinically and ethically relevant information to patients.
AMA J Ethics. 2018;20(9):E804-811. doi:
10.1001/amajethics.2018.804.
Dr Whitney Riley Linsenmeyer joins Ethics Talk to discuss her article, coauthored with Dr Sarah Garwood: “Patient-Centered Approaches to Using BMI to Evaluate Gender-Affirming Surgery Eligibility.”
Dania Pagarkar joins Ethics Talk to discuss her article, coauthored with Drs Erin Harrop and Lisa Erlanger: “How Should We Approach Body Size Diversity in Clinical Trials?”